TEL AVIV, Israel, March 26, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that its stock has been approved to list on the Nasdaq Global Market, effective with the open of the stock market on Friday, March 28, 2014. Until the stock is transferred to Nasdaq Global Market, ADHD's stock will continue to trade on the Nasdaq Capital Market. The company will continue to trade under its existing ticker symbol "ADHD."
The listing requirements for the NASDAQ Global Market are more stringent than those for the NASDAQ Capital Market, and are based on certain financial and liquidity requirements, such as income from continuing operations, stockholders equity, market capitalization, total assets and revenue, publicly held shares, market value of publicly held shares, minimum bid price, round-lot shareholders, market makers, and operating history.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts: LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 firstname.lastname@example.org